Dividend Win Wednesday: Insiders Buy $20M While Gold and Energy Sit 18% Below Highs

This Week's Setup

The dividend screener parks gold and energy at the top four ranks with FCF yields above 4.6% and drawdowns stretching to 18%, while pharma names land in the middle with narrower pullbacks and fat gross margins. Newmont and ConocoPhillips show directors buying five- and six-figure blocks in May, and Gilead insiders added $6.1 million of shares even as the stock trades 18% below its peak.

S&P 500 CAPE at 38.9 continues to price in flawless execution for the index while these eight names yield 2.6% to 3.7% and trade 8% to 20% below 52-week highs, creating a spread that history flags as actionable.

Quick Scan

The 8 Names

1. Newmont Corporation (NEM)

Dividend yield: 0.95% | Payout ratio: 15.7% | 52w drawdown: -18.7%

Newmont delivers 6.2% FCF yield and 29.8% ROIC while revenue grew 21% year-over-year, a combination that typically accompanies operational leverage in a capital-intensive miner. The normalized P/E of 14.2 and EV/EBITDA of 6.9 sit well below the historical multiple for a tier-one gold producer, and analyst consensus at $142.82 implies 30% upside from the current $109.71 print.

Directors Deborah Leyva, David Thornton, and Maura Clark each filed Form 4s between May 4 and May 15, adding 16,605 net shares at a $5.03 insider sentiment score. The timing follows RBC's May adjustment to $140 from $160 with an Outperform rating maintained, signaling that the sell-side reset expectations while insiders added exposure.

Net debt-to-EBITDA of -0.20 means Newmont holds net cash, but the 18.7% drawdown reflects market skepticism that gold will hold above $2,400 per ounce through year-end. If spot gold reverts to $2,100, the FCF cushion compresses and the dividend coverage deteriorates despite the 15.7% payout ratio today.

2. ConocoPhillips (COP)

Dividend yield: 2.87% | Payout ratio: 51.3% | 52w drawdown: -13.9%

ConocoPhillips trades at 5.1% FCF yield and 19.9× earnings with 13.5% ROIC, a setup that historically precedes outperformance when crude stabilizes above $70 Brent. The 2.9% dividend yield and 3.6% shareholder yield combine with analyst targets at $142.77 to frame a 22% upside path from $116.97, and the 51% payout ratio leaves room for distribution growth if free cash flow continues its current trajectory.

Jaramillo Mejia Ricardo, Mejia Cardona Andres Felipe, and Escovar Gomez Sylvia each filed buys in late May, adding 256,539 net shares at a $6.01 insider sentiment score. The cluster of executive adds at 1.19% buy versus 0.99% sell suggests management confidence that the Marathon Oil integration will accrete faster than the Street models.

Revenue fell 4.5% year-over-year and the 10-year earnings yield sits at 0.58%, flagging that the last decade of upstream economics has been mediocre for equity holders. If WTI rolls over to $60, the shareholder yield shrinks and the 14% drawdown becomes a preview of deeper losses rather than an entry point.

3. Novartis AG (NVS)

Dividend yield: 3.30% | Payout ratio: 64.7% | 52w drawdown: -15.8%

Novartis posts 5.6% FCF yield, 16% ROIC, and 75.8% gross margins while growing revenue 9.6% year-over-year, a combination that reflects the company's pivot toward higher-margin specialty medicines. The 3.3% dividend yield with 7.2% five-year dividend CAGR and 64.7% payout ratio creates a durable income stream, and the 15.8% drawdown aligns with sector rotation rather than franchise deterioration.

The normalized P/E of 20.6 and EV/EBITDA of 13.9 sit at the high end of historical ranges for a large-cap pharma, and the net debt-to-EBITDA of 1.75 limits capital flexibility if late-stage pipeline assets require emergency funding. Analyst targets at $153.87 imply only 7.2% upside, the narrowest margin of safety in this week's top eight.

Insider sentiment sits at 5.00 with zero net shares purchased in the last six months, a neutral signal that contrasts with the conviction buying at Newmont and ConocoPhillips. If the next earnings report on July 21 misses the $2.11 EPS estimate or revenue guidance softens, the 15.8% drawdown becomes the first leg of a deeper correction rather than a discount entry.

4. Biogen Inc. ([BIIB])

Dividend yield: n/a | Payout ratio: 0.0% | 52w drawdown: -8.2%

Biogen delivers 7.1% FCF yield and 75.7% gross margins even as it carries no dividend, a capital allocation decision that funnels all free cash into buybacks and pipeline investment. The 8.2% drawdown is the narrowest in this week's screen, and analyst targets at $219.44 frame 16.1% upside from the $189.01 current price with July 30 earnings the next catalyst.

Insiders added $7.42 million and 84,208 net shares in the last six months, with Adam Keeney filing a Form 4 on May 5. The 50.4% buy versus 2.0% sell ratio signals management conviction that the Alzheimer's franchise and kidney disease pipeline will outperform Street expectations through the second half of 2026.

Revenue growth of 2.2% year-over-year and net debt-to-EBITDA of 0.64 flag that Biogen is not yet in high-growth mode, and the absence of a dividend means equity holders bear all downside if the neuroscience pipeline stumbles. Short interest at 3.2% of float is the highest in this week's top eight, reflecting skepticism that the stock deserves a 20.3× P/E multiple without a clearer path to double-digit revenue expansion.

5. EOG Resources, Inc. (EOG)

Dividend yield: 2.94% | Payout ratio: 43.6% | 52w drawdown: -8.5%

EOG trades at 4.7% FCF yield, 15.2% ROIC, and 7.3% earnings yield while sitting 8.5% below its 52-week high, a valuation profile that typically precedes outperformance when crude stabilizes. The 2.9% dividend yield and 3.5% shareholder yield combine with analyst targets at $160.25 to frame 15.3% upside from $138.97, and the 43.6% payout ratio leaves capital for both distributions and organic drilling.

Directors Lynn Dugle, Charles Crisp, and Jeffrey Leitzell added 138,766 net shares between May 4 and May 28, pushing insider sentiment to 5.50 with 11.4% buy versus 1.3% sell. The timing follows Capital One's May adjustment to $159 from $161 with an Overweight rating maintained, suggesting directors used the modest price target cut as an entry window.

Revenue fell 3.4% year-over-year and the 10-year earnings yield of 2.9% flags that the last decade delivered mediocre equity returns despite the strong current-year cash generation. If WTI breaks below $65, the FCF yield compresses and the 8.5% drawdown becomes a preview of deeper losses rather than a dip-buying opportunity.